A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF QUIZARTINIB (AC220)MONOTHERAPY VERSUS SALVAGE CHEMOTHERAPY IN SUBJECTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) REFRACTORY TO OR RELAPSED AFTER FIRST-LINE TREATMENT WITH OR WITHOUT HEMATOPOIETIC STEM CEL
(Leukämie, Blutkrebs, AML, akute myeloblastische Leukämie, weiße Blutkörperchen, Blut, blutbildendes System, Leukozyten)
